Inhibition of Bacterial and Fungal Biofilm Formation by 675 Extracts from Microalgae and Cyanobacteria by Cepas, Virginio et al.
antibiotics
Article
Inhibition of Bacterial and Fungal Biofilm Formation
by 675 Extracts from Microalgae and Cyanobacteria
Virginio Cepas 1 , Yuly López 1, Yaiza Gabasa 1, Clara B. Martins 2, Joana D. Ferreira 2,
Maria J. Correia 2, Lília M.A. Santos 2, Flávio Oliveira 3, Vitor Ramos 3 , Mariana Reis 3,
Raquel Castelo-Branco 3, João Morais 3 , Vitor Vasconcelos 3,4 , Ian Probert 5, Emilie Guilloud 5,
Mohamed Mehiri 6 and Sara M. Soto 1,*
1 ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain;
virginio.cepas@isglobal.org (V.C.); yuly.lopez@isglobal.org (Y.L.); gabasagyaiza@gmail.com (Y.G.)
2 Coimbra Collection of Algae (ACOI), Department of Life Sciences, University of Coimbra, 3000-456 Coimbra,
Portugal; martinscsb@gmail.com (C.B.M.); ferreirajoanadias@gmail.com (J.D.F.);
mariajacorreia1@gmail.com (M.J.C.); liliamas@ci.uc.pt (L.M.A.S.)
3 Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), 4450-208 Porto, Portugal;
up201510053@fc.up.pt (F.O.); vtr.rms@gmail.com (V.R.); mariana.a.reis@gmail.com (M.R.);
raquel.castelobranco.12@gmail.com (R.C.-B.); joaopmorais@gmail.com (J.M.); vmvascon@fc.up.pt (V.V.)
4 Faculty of Sciences, University of Porto, 4450-208 Porto, Portugal
5 Roscoff Culture Collection, Sorbonne University/CNRS, Roscoff Biological Station, 29680 Roscoff, France;
probert@sb-roscoff.fr (I.P.); emilie.guilloud@gmail.com (E.G.)
6 Marine Natural Products Team, Nice Institute of Chemistry, UMR 7272 University Nice Côte d’Azur/CNRS,
60103 Nice, France; Mohamed.MEHIRI@unice.fr
* Correspondence: sara.soto@isglobal.org; Tel.: +34-93-227-5707
Received: 13 May 2019; Accepted: 5 June 2019; Published: 12 June 2019


Abstract: Bacterial biofilms are complex biological systems that are difficult to eradicate at a medical,
industrial, or environmental level. Biofilms confer bacteria protection against external factors and
antimicrobial treatments. Taking into account that about 80% of human infections are caused by
bacterial biofilms, the eradication of these structures is a great priority. Biofilms are resistant to
old-generation antibiotics, which has led to the search for new antimicrobials from different sources,
including deep oceans/seas. In this study, 675 extracts obtained from 225 cyanobacteria and microalgae
species (11 phyla and 6 samples belonging to unknown group) were obtained from different culture
collections: The Blue Biotechnology and Ecotoxicology Culture Collection (LEGE-CC), the Coimbra
Collection of Algae (ACOI) from Portugal, and the Roscoff Culture Collection (RCC) from France.
The largest number of samples was made up of the microalgae phylum Chlorophyta (270) followed
by Cyanobacteria (261). To obtain a large range of new bioactive compounds, a method involving
three consecutive extractions (hexane, ethyl acetate, and methanol) was used. The antibiofilm
activity of extracts was determined against seven different bacterial species and two Candida strains
in terms of minimal biofilm inhibitory concentration (MBIC). The highest biofilm inhibition rates
(%) were achieved against Candida albicans and Enterobacter cloacae. Charophyta, Chlorophyta, and
Cyanobacteria were the most effective against all microorganisms. In particular, extracts of Cercozoa
phylum presented the lowest MBIC50 and MBIC90 values for all the strains except C. albicans.
Keywords: Marine sources; Microalgae; Cyanobacteria; Antibiofilm
1. Introduction
Bacterial biofilms are formed by aggregates of microorganisms within a complex biological
system composed of assemblages of sessile cells adherent to each other or to a surface. Biofilms are
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embedded in an extracellular polymeric substance (EPS) matrix composed mainly of polysaccharides,
lipids, proteins, and external DNA (eDNA) [1]. Biofilms provide bacteria protection against external
factors such as temperature, pH variations, desiccation, oxidization, ultraviolet radiation, and metal
ions. Furthermore, biofilms are able to evade innate and/or adaptive immune defenses and avoid
antimicrobial treatments by several mechanisms [2–4]. Biofilms have the capacity to attach to both biotic
and abiotic surfaces, increasing the colonization of medical devices such as urinary and intravenous
catheters, mechanical heart valves, endotracheal tubes, and prosthesis joints [5]. In fact, the National
Institute of Health (NIH—United States of America) recognizes that 80% of human infections are
caused by bacterial biofilms [6,7]. In the United States, biofilm-related infections affect over 12 million
people with an estimated annual economic burden of 6 billion dollars [8].
On the other hand, in the last several decades, antimicrobial resistance (AMR) has increased
becoming a serious problem worldwide. Infections caused by drug-resistant bacteria increase the risk
of death compared with non-resistant bacteria. However, the emergence of antimicrobial resistant
microorganisms has been accompanied by a decrease in the number of new antibacterial agents in
the market. Indeed, only two new classes of anti-bacterial drugs have been marketed in the last
60 years: linezolid representing the oxazolidinone group, and daptomycin representing the lipopeptide
group [9]. The problem of AMR is further enhanced when current treatments cannot completely
eradicate persistent cells that remain inside the biofilm. There is a well-established correlation between
bacterial persistence and microorganisms able to form biofilm [10].
In addition, apart from bacterial infections rising in hospitals, the incidences of fungal infections
are growing with the development of resistance to conventional antifungal agents [11]. The complex
three-dimensional structures of biofilms form a favorable environment for micro niches of Candida
species. The biofilm occurrence of these organisms contributing to numerous infections [12]. The fungal
pathogen most commonly associated with biofilm infections is Candida albicans, these infections being
associated with a high mortality. The most common sites for fungal infections associated with biofilms
are the oral cavity, lungs, burn wounds, the lower reproductive tract, the gastrointestinal tract, skin,
intravascular and the insertion site of urinary catheters [13]. Thus, C. albicans and C. parapsilosis are
two of the Candida species more frequently associated with symptomatic vulvovaginal candidiasis,
biofilm formation being essential for the development of this type of infection [14]. These structures
confer Candida species a high resistance to the antifungal used in their treatment.
Therefore, the importance of finding new bioactive compounds arises from global bacterial
resistance to existing antibiotics. One of the possible sources of new antibiofilm and antimicrobial
agents are marine organisms such as macroalgae, microalgae, bryozoans, cnidarians, echinoderms,
sponges, molluscs, tunicates, marine fungi, and marine bacteria [15]. Indeed, in 2015, 1340 new marine
natural products (MNPs) were reported to have potential efficacy against cancer, viruses, bacteria,
fungi, hypertension, high cholesterol, and other diseases [16]. Nevertheless, antimicrobial activity has
been detected in 262 marine compounds including alkaloids, terpenoids, lipids, peptides, halogenated
compounds, polyketides, isocumarins, nucleosides, and other minority compounds found in MNPs [17].
Several studies have described the antimicrobial activity of a very diverse array of MNPs from marine
species [16,18]. In particular, microalgae derivatives may be potentially promising candidates for
the development of novel antibacterial drugs because of their ability to combat pathogenic bacteria
found throughout the ocean [19,20]. These microorganisms have been described as rich sources of
several bioactive compounds such as proteins, fatty acids, vitamins, and pigments [20]. Additionally,
the coexistence of several species in aquatic systems creates a competitive niche that can lead them
to release compounds into the environment in order to facilitate advantage over competitors [21].
These compounds have shown antifungal, antiviral, antialgal, antienzymatic, or antibiotic activity [20].
Lipids such as short-chain fatty acids and PUFAs (polyunsaturated fatty acids) have been associated
with antibacterial properties [22,23]. Nonetheless, there is a lack of data related to antibiofilm activity
of MNPs obtained from microalgae and cyanobacteria species, with the exception of a single brief
reference [24].
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The aim of the present study was to determine the antibiofilm activity of microalgae and
cyanobacteria species against nine biofilm-forming human pathogens, representing the most important
Gram-positive, Gram-negative, and fungal species, to search for new bioactive antibiofilm compounds
using the biofilm inhibition ratio (%) and minimal biofilm inhibitory concentration (MBIC) assay.
2. Results
The results showed that 205 hexane extracts exhibited the best antibiofilm activity, followed by
195 extracts obtained with methanol and 189 extracts presenting inhibitory activity obtained with ethyl
acetate. The rest of the extracts did not show any antibiofilm activity. Nevertheless, no significant
activity was reported between methods of extraction (p > 0.05) (Table S1). The small differences in
activity among the three solvents suggested that the three solvent protocol covers a large range of
compounds with different polarities, and it is more effective than extraction with only one solvent.
Figure 1 provides an overview of the biofilm inhibition ratio (%) per group and solvent. The highest
inhibition ratios were reported in C. albicans and E. cloacae in all solvents. Interestingly, C. albicans
showed high inhibition rates above 50% of inhibition in all samples, with the exception of Glaucophyta
and Miozoa methanol extracts (28.2% and 12.55%, respectively) and Rhodophyta hexane extract (34.77%).
High biofilm inhibition ratios, about 35%, were found for E. cloacae. These rates were lower compared to
C. albicans but still, more active in comparison with the rest of microorganisms. In the case of E. cloacae,
only the methanol extract from the Miozoa phylum showed activity below 35% (9.38%). Biofilm
inhibition of the nine microorganisms tested was individually analyzed in Figure 2. The inhibition
rates in both cases were remarkably high and almost 50% of inhibitions were above the median value.
On the other hand, in the case of S. hominis, only the methanol extract from Miozoa was able to inhibit it
up to 64.22%. In addition, extract obtained from Cercozoa and Euglenophyta did not present activity
against S. aureus.
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Figure 2. Individual biofilm inhibition ratios of Charophyta, Chlorophyta, and Cyanobacteria extracts
against E. cloacae and C. parapsilopsis, represented as percentages. (a): Charophyta against E. cloac e;
(b) Chlorophyta against E. cloacae; (c) Cyanobacteria against E. cloacae; (d) Charophyta against C. albicans;
(e) Chlorophyt against C. albicans; (f) Cyanobacteri C a bicans.
Only the results from phyla with a high number of extracts tested (Charophyta, Chlorophyta and
Cyanobacteria) were statistically analyzed. The two-way ANOVA howed that both solvents nd
ph lum significantly influenced the biofilm formation rates (p < 0.001) compared to growth co trol.
To further investigate which phylum and meth d of extraction (solvent) was mo e effective in
biofilm inhibition, Tukey’s multiple compariso test was also performed. Charophyta presented the best
inhibition ratios against E. coli, P. aeruginosa, S. aureus, S. epidermidis, and C. parapsil sis (Tables S2–S4).
Cyanobacteria induced biofilm inhibition versus K. pne moniae and S. hominis. On the other hand, the
three phyla presented the sam effectiveness against both C. albicans and E. cloacae (Tables S2–S4).
C. albicans and C. parapsilopsis wer inhibit d by 308 extracts. Biofilm formation among
Gram-negative strains was inhibited by 202 extracts (30%) with equal distribution among species.
Among Gram-positive str ins, biofilm formation was inhibited by 69 of the 675 samples (10.2%).
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Cercozoa and the unknown group showed activity at the lowest concentration in all the groups of
microorganisms, except for C. albicans. Among all microorganism, the Cryptophyta, Euglenophyta, and
Glaucophyta groups showed the best antibiofilm activity.
The Cercozoa presented an MBIC50 of 32 and an MBIC90 of 128 µg/mL in E. coli, K. pneumoniae,
E. cloacae, S. aureus, and C. parapsilopsis, whereas among S. epidermidis and S. hominis the MBIC50 and
MBIC90 were 64 and 256 µg/mL, respectively. P. aeruginosa showed the lowest inhibitory concentrations,
with MBIC50 and MBIC90 values of 16 and 64 µg/mL, respectively.
The unknown group (represented by two species) presented the highest activity in all
microorganisms except for E. cloacae. Thus, the MBIC50 was 64 µg/mL, and the MBIC90 was 256 µg/mL
for E. coli, P. aeruginosa, and C. parapsilopsis. K. pneumoniae and S. hominis showed MBIC50 and MBIC90
values of 64 and 128 µg/mL, respectively. Finally, S. aureus and S. epidermidis presented an MBIC50 of
128 µg/mL and an MBIC90 of 256 µg/mL.
Among the Gram-negative bacteria (Table 1), E. cloacae was inhibited by the lowest MBIC values
of all the extracts tested. In addition to the results described above, the Cryptophyta and Rhodophyta
phyla demonstrated activity against E. cloacae with an MBIC50 and an MBIC90 ranging from 16 to
256 µg/mL and from 16 to 128 µg/mL, respectively.
Individually, Rhodophyta showed antibiofilm activity against E. coli with MBIC50 and MBIC90
values of 64 and 512 µg/mL, respectively.
The Cryptophyta showed activity against P. aeruginosa with MBIC50 and MBIC90 values of 64 and
512 µg/mL, respectively.
Among Gram-positive bacteria (Table 2), S. hominis was inhibited by the lowest MBIC values of
all the extracts studied. In addition to Cercozoa and the unknown group, the Miozoa showed MBIC50
and MBIC90 values of 128 and 1024 µg/mL, respectively. The activity of the Miozoa was only of note in
S. hominis. Moreover, the Haptophyta demonstrated activity against S. aureus with MBIC50 and MBIC90
values of 128 and 512 µg/mL, respectively. Finally, S. epidermidis presented an MBIC50 of 256 µg/mL
and an MBIC90 of 1024 µg/mL.
Among Candida spp., the greatest activity was reported in C. albicans (Table 3). Three of the
11 groups were able to inhibit biofilm formation with MBIC50 values of 8 µg/mL. The lowest activity was
reported by the Euglenophyta with an MBIC50 of 8 µg/mL and an MBIC90 of 16 µg/mL. Similar results
were found with the Cryptophyta showing also an MBIC50 of 8 µg/mL and an MBIC90 of 128 µg/mL.
Finally, the Glaucophyta presented an MBIC50 and an MBIC90 of 8 and 256 µg/mL, respectively.
Interestingly, the Euglenophyta and Glaucophyta were only active against biofilm formation in C. albicans.
On the other hand, Rhodophyta species demonstrated activity against C. parapsilopsis with an
MBIC50 of 64 µg/mL and an MBIC90 of 512 µg/mL.
3. Discussion
The present study was designed to determine the effect of new bioactive compounds from
microalgae and cyanobacteria species on biofilm formation. We focused on these microorganisms
because they are widely distributed in marine and freshwaters and are an important population
in all strata, contributing as primary producers in open water systems [25–28]. Crude extracts are
a heterogeneous mixture of polar and non-polar compounds. The selection of an efficient method
of extraction is important for performing successive assays. For that reason, we used a method
combining three different solvents (hexane [non-polar], ethyl acetate [polar], and methanol [polar])
for extracting a wide range of biological samples in order to collect the greatest range of polar and
non-polar compounds.
The purpose of hexane is to extract polar compounds from the mixture, such as triacylglycerides
(TAG), while methanol and ethyl acetate, polar solvents, can extract many biological compounds (polar
and non-polar metabolites), such as fatty acids (FA).
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Table 1. Antibiofilm activity against Gram-negative bacteria of marine natural products. Range: range of concentrations tested; MBIC50: lowest concentration of the
test compound that resulted in ≥50% inhibition of biofilm formation; MBIC90: lowest concentration of the test compound that resulted in ≥90% inhibition of biofilm
formation; GM: geometric mean. MBICs are reported in µg/mL.
Phylum Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Pseudomonas aeruginosa
Range MBIC50 MBIC90 GM Range MBIC50 MBIC90 GM Range MBIC50 MBIC90 GM Range MBIC50 MBIC90 GM
Cercozoa 32–128 32 128 50.8 32–128 32 128 50.8 32–128 32 128 50.8 16–64 16 64 25.4
Charophyta 32–2048 256 512 82.5 32–2048 256 512 69.4 16–2048 256 512 145.3 64–2048 256 1024 326.3
Chlorophyta 8–4096 512 1024 301.7 8–4096 512 1024 315.2 2–4096 256 1024 288.1 8–4096 512 1024 315.2
Cryptophyta 16–1024 64 1024 101.6 8–1024 64 1024 90.5 4–256 16 256 22.6 8–512 64 512 64.0
Cyanobacteria 8–2048 128 1024 153.7 16–2048 256 1024 197.3 8–2048 256 512 186.6 8–2048 128 512 168.7
Euglenophyta 64–256 128 256 128.0 64–256 64 256 101.6 64–256 128 256 128.0 64–256 128 256 128.0
Glaucophyta 64–1024 256 1024 256.0 64–1024 256 1024 256.0 64–512 256 512 228.1 64–1024 256 1024 256.0
Haptophyta 16–512 128 512 136.3 16–512 128 512 128.0 4–512 64 512 72.6 8–512 64 256 82.3
Miozoa 32–1024 64 1024 122.2 32–1024 64 1024 116.7 16–1024 64 1024 101.6 32–1024 64 1024 111.4
Ochrophyta 32–1024 128 512 149.3 64–1024 128 512 157.2 8–512 64 512 91.7 32–1024 128 512 149.3
Rhodophyta 32–512 64 512 90.5 32–512 64 512 90.5 4–128 16 128 22.6 32–256 64 256 80.6
Unknown 16–256 64 256 71.8 16–128 64 128 64.0 16–128 64 128 64.0 16–256 64 256 71.8
Table 2. Antibiofilm activity against Gram-positive bacteria of marine natural products. Range: range of concentrations tested; MBIC50: lowest concentration of the
test compound that resulted in ≥50% inhibition of biofilm formation; MBIC90: lowest concentration of the test compound that resulted in ≥90% inhibition of biofilm
formation; GM: geometric mean. MBICs are reported in µg/mL.
Phylum Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis
Range MBIC50 MBIC90 GM Range MBIC50 MBIC90 GM Range MBIC50 MBIC90 GM
Cercozoa 32–128 32 128 50.8 64–256 64 256 101.6 64–256 64 256 101.6
Charophyta 64–4096 512 1024 542.4 64–4096 512 1024 588.1 64–4096 512 1024 530.1
Chlorophyta 8–8192 512 2048 469.2 8–8192 512 2048 472.8 8–8192 256 1024 291.1
Cryptophyta 32–2048 128 2048 203.2 32–2048 128 2048 203.2 32–2048 128 2048 203.2
Cyanobacteria 16–4096 256 2048 297 16–4096 256 10,248 339.2 16–4096 256 2048 255.3
Euglenophyta 128–512 256 512 256 128–512 256 512 256 128–512 256 512 256
Glaucophyta 128–2048 512 2048 512 128–2048 512 2048 512 128–2048 512 2048 512
Haptophyta 32–1024 128 512 120.8 32–1024 256 1024 170.9 32–1024 256 1024 170.9
Miozoa 32–2048 128 1024 194 64–2048 128 1024 222.9 16–2048 128 1024 154
Ochrophyta 128–1024 256 1024 298.6 128–1024 256 1024 314.4 128–1024 256 512 249.5
Rhodophyta 64–128 128 1024 181 64–128 128 1024 181 64–128 128 1024 181
Unknown 16–256 128 256 101.6 32–256 128 256 114 2–128 64 128 45.3
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Table 3. Antibiofilm activity against Candida spp. of marine natural products. Range: range of
concentrations tested; MBIC50: lowest concentration of the test compound that resulted in ≥50%
inhibition of biofilm formation; MBIC90: lowest concentration of the test compound that resulted in
≥90% inhibition of biofilm formation; GM: geometric mean.
Phylum Candida albicans Candida parapsilosis
Range MBIC50 MBIC90 GM Range MBIC50 MBIC90 GM
Cercozoa 32–64 32 64 40.3 32–128 32 128 80.8
Charophyta 8–128 16 64 23.7 32–4096 256 512 284
Chlorophyta 2–2048 32 256 44.7 8–4096 256 1024 224.6
Cryptophyta 4–128 8 128 12.7 16–1024 64 1024 101.6
Cyanobacteria 2–2048 32 256 39.6 16–4096 256 1024 186.6
Euglenophyta 8–16 8 16 12.7 64–256 128 256 128
Glaucophyta 4–256 8 256 16 64–1024 256 1024 256
Haptophyta 0.5–256 32 128 20.2 16–512 128 512 90.5
Miozoa 8–512 32 256 44.2 32–1024 64 1024 122.2
Ochrophyta 4–256 32 256 27.4 64–1024 128 512 165.5
Rhodophyta 8–64 16 64 20.2 32–512 64 512 90.5
Unknown 16–64 32 64 28.5 16–256 64 256 64
In fact, previous studies have reported that FA have the ability to inhibit biofilm formation.
For example, oleic acids block bacterial adhesion in S. aureus [29]. The cis-2-decenoic acid synthetized
by P. aeruginosa is able to induce the dispersion of established biofilms and inhibit biofilm formation [30].
Indeed, recent studies have demonstrated that small FA messengers inhibit cell–cell
communication, achieving biofilm dispersion and are considered to be a quorum sensing inhibitor [31].
Hence, with three consecutive extraction solvents we were able to collect a wide range of lipids including
fatty acids (FA), waxes, sterols, hydrocarbons, ketones, and pigments (carotenoids, chlorophylls,
and phycobilins) [32], which have been described as possessing high antibacterial and antibiofilm
activity [23,33]. The findings of the one-way ANOVA data support the claim that three solvents are
necessary to obtain a wide range of molecules.
Only three phyla (Charophyta, Chlorophyta, and Cyanobacteria) were included in the two-way
ANOVA analysis due to the number of samples extracted. Nevertheless, the fact that the other
phyla showed interesting levels of biofilm inhibition rates (Figure 1) suggests that they are also good
candidates for further studies.
The MBIC assay was used to determine the effectiveness of the sample extractions against biofilm
producer microorganisms. Among bacteria, lower extract concentrations are needed to inhibit biofilm
formation in Gram-negative in comparison with Gram-positive bacteria. Among the yeasts, lower
extract concentrations are needed to inhibit biofilm formation in C. albicans compared to C. parapsilopsis.
This finding was unexpected, and these extracts are being further investigated in an attempt to elucidate
the mechanism underlying the antifungal action of these extracts.
The microalgae and cyanobacteria from which extracts generated were very diverse, and differences
were observed in the level of bioactivity of different groups.
It is interesting to note that extracts from the Cercozoa phylum were very active against the eight
target microorganisms in this study, except C. albicans, which was relatively unaffected. The Cercozoa
phylum is a very diverse lineage of unicellular amoeboid organisms that are mostly heterotrophic and
that can have a very complex cellular ultrastructure and behavioral patterns. Common examples in
marine environments include the biomineralizing radiolarians and Foraminifera. A single relatively
minor group within this lineage, the chlorarachniophytes, has acquired green chloroplasts by secondary
endosymbiosis at some point in its evolutionary history and therefore qualifies as microalgae. Very little
is known about the ecology or metabolism of the 14 described species in this group, but members
appear to be good candidates for further investigation in the context of the search for new bioactive
molecules. However, these data should be interpreted with caution because the Cercozoa phylum was
represented by only three marine culture strains in our study, all of which are relatively difficult to
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grow (low growth rates and maximum cell abundances, adherence to the surface of culture vessels),
meaning scale-up of cultures is likely to be challenging.
Several studies have described antimicrobial activities in microalgae and cyanobacteria species [34],
but no results about antibiofilm against clinical pathogens, except those from Lauritano et al. [24], have
been reported to date. Lauritano’s group found two species belonging to the Leptocylindrus genus
showing strong antibiofilm activity against S. epidermidis when they are grown in N-starved medium.
This issue may be important since resistance against antimicrobial agents changes depending
on the expression of the phenotype. Planktonic microorganisms show greater susceptibility against
the current therapies available than biofilm-forming microorganisms [35,36]. On the other end of the
bioactivity spectrum, the Chlorophyta and Charophyta, which are both lineages of green microalgae,
consistently had high average MBIC values. The Chlorophyta are known for their ability to synthesize a
variety of bioactive compounds such as lipids and derivative polyunsaturated fatty acids (PUFAs).
Two PUFAs, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have been demonstrated
to exhibit antibacterial and antibiofilm properties [36,37]. Extracts from some chlorophyte strains had
very low MBIC values and the high average values may be a reflection of the fact that the Chlorophyta
was the most represented phylum in our study. Some microalgal groups appear to be specifically
active against certain pathogens. For instance, extracts from Rhodophyta species exhibited relatively
high antibiofilm activity against E. cloacae, while biofilm formation in C. albicans was particularly
sensitive to extracts from Cryptophyta, Euglenophyta, and Glaucophyta (three completely unrelated
lineages). Phyla such as Cyanobacteria, Haptophyta and Ochrophyta genera, all of which were fairly
well represented in our study, consistently exhibited intermediate average MBIC values. These results
can be explained due to several secondary metabolites such as circular or linear lipopeptides, amino
acids, FA, macrolides, and amides with antibacterial activity [21].
4. Materials and Methods
4.1. Microalgae and Cyanobacteria Extracts
A total of 225 species of microalgae and cyanobacteria (belonging to the phyla Cercozoa, Charophyta,
Chlorophyta, Cryptophyta, Cyanobacteria, Euglenophyta, Glaucophyta, Haptophyta, Miozoa, Ochrophyta,
Rhodophyta, and 2 unknown species) were tested. They were supplied by Blue Biotechnology and
Ecotoxicology Culture Collection (LEGE-CC) at CIIMAR, Centro Interdisciplinar de Investigação
Marinha e Ambiental (CIIMAR) [38], the Coimbra Collection of Algae, University of Coimbra (ACOI),
and the Université Pierre et Marie Curie-Paris 6 (UPMC). ACOI microalgae strains were collected
mainly from freshwater habitats in Portugal. Cyanobacteria were collected mainly from beaches along
the Portuguese coast (Atlantic Ocean) but also from brackish and freshwater systems (rivers, lakes, and
estuaries). Only one of the cyanobacteria strains tested in this study was isolated from Chile (lake).
Microalgae cultures were performed by CIIMAR, ACOI, and UPMC. Briefly, samples were
cultured until stationary phase for 15 or 30 days, depending on the strain, with air bubbling, and
temperature and pH ranged between 20 and 30 ◦C and between 6 and 8, respectively.
The growth media used for microalgae culture were M7, BG-11 (Sigma-Aldrich C3061, Darmstadt,
Germany), S2T2, and LC. Each culture was illuminated 14–16 h every day with fluorescent lamps at an
intensity of 30–60 µmol/m2/s or 100–200 µmol/m2/s depending on the strain.
Cyanobacteria strains were cultured for 30–45 days, depending on the strain, without bubbling,
with daily manual shaking between 30 s and 1 min every day and temperature ranging between 25
and 30 ◦C. To culture cyanobacteria Z8 [39] and modified Z8 medium supplemented with 25 g/L of
synthetic sea salts (Tropic Marin, Juliao do Tojal, Portugal) and B12 vitamin were used. The Z8 medium
was supplemented because all marine cyanobacterial strains require artificial salts and some of them
require the vitamin to grow. Cultures were performed under 14 h light /10 h dark cycles with a light
intensity of 10–30 mol photons/m2/s).
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Microalgae biomass was collected by centrifugation at 4000 rpm for 15 min. Pellets were frozen
at −80 ◦C and lyophilized. Freeze-dried biomass was disrupted using a ceramic mortar, previously
exposed to liquid nitrogen or with ultrasounds at 240 W, 35 kHz for 5 min.
Sequential extractions from hexane (non-polar), ethyl acetate to methanol (polar) were carried
out. Each pellet was extracted by adding 3 × 20 mL of each solvent to centrifuge tubes, occasional
vortexing and centrifuged at 4500 rpm for 15 min. Supernatant was recovered, transferred to glass
vials, and fully dried in the rotary evaporator. Extracts were stored under dark dry conditions until
use to avoid hydrolysis of bioactive molecules. The extracts were resuspended in 1 mL of 6% dimethyl
sulfoxide (DMSO) (Panreac Applichem, Barcelona, Spain) immediately before the bioassay.
4.2. Microorganisms and Culture Conditions
Bacterial strains were stored in skim milk (BD) at −80 ◦C. In the present study, the strains were
characterized in terms of biofilm formation, using the crystal violet protocol, as is shown in Table 4.
E. coli, K. pneumoniae, E. cloacae, and P. aeruginosa were cultured for 24 h at 37 ◦C in aerobic conditions
in Luria Broth agar (Condalab, Barcelona, Spain).
Table 4. Biofilm values obtained by crystal violet elution of each microorganism analyzed in this study.
OD580 (optical density at 580 nm).
Microorganism Strains OD580 Type
Escherichia coli 1.552 Bacteria
Klebsiella pneumoniae 0.934 Bacteria
Enterobacter cloacae 0.879 Bacteria
Pseudomonas aeruginosa 0.701 Bacteria
Staphylococcus aureus 0.918 Bacteria
Staphylococcus epidermidis 1.129 Bacteria
Staphylococcus hominis 0.940 Bacteria
Candida albicans 1.014 Yeast
Candida parapsilosis 1.301 Yeast
S. aureus, S. epidermidis, and S. hominis were plated on Columbia agar with 5% sheep blood agar
(Becton Dickinson, Huesca, Spain) for 24 h at 37 ◦C in aerobic conditions.
Candida spp. strains were cultured for 24 h at 37 ◦C in Saboroud Agar (Becton Dickinson,
Huesca, Spain).
4.3. Minimal Biofilm Inhibitory Concentration (MBIC)
The MBIC assay was performed by the broth microdilution assay described in the CLSI document
M7-A7 with some modifications [40]. The culture media used for biofilm formation experiments
was M63 supplemented with 0.25% glucose for E. coli, Luria Bertani broth supplemented with 0.25%
glucose for K. pneumoniae and P. aeruginosa, Tryptic Soy Broth (TSB) supplemented with 0.25% glucose
for Gram-positive bacteria, and Yeast Nitrogen Base (YNB) for Candida spp. These culture media
improve the biofilm formation in the corresponding bacterial specie.
For all strains, with an exception of C. albicans, two-fold dilution series of each microalgae extract
in culture media was inoculated with 50 µL of a 0.5 McFarland Standard (corresponding to an inoculum
of 5 × 106 cells/well) and incubated for 48 h at 37 ◦C (or 30 ◦C in the case of E. coli) in aerobic conditions
without shaking. A negative control (culture medium without inoculum) and a positive control (culture
medium with inoculum) were included in each plate. All the plates were covered with adhesive foil
lids to avoid evaporation.
The biofilm susceptibility assay for P. aeruginosa was performed using the Calgary protocol as
described previously [41] with one modification. The bacterial biofilm was formed by immersing the
pegs of a modified polystyrene microtiter lid (catalog no. 445497; Nunc TSP system, Nunc, Roskilde,
Denmark).
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For Candida spp., a loopful of yeasts, from overnight culture, were washed twice with 3 mL of
phosphate-buffered saline (PBS; pH 7.2; Ca2+ and Mg2+-free), and the optical density of the suspension
was adjusted to 0.38 at 520 nm. Two-fold dilution series of each microalgae extract in culture media
was inoculated with 50 µL of a 0.38 OD (corresponding to an inoculum of 5 × 106 cells/well) and
incubated for 48 h at 37 ◦C in aerobic conditions without shaking.
For all microorganisms, after incubation, liquid culture was carefully removed and washed once
with PBS and dried at 65 ◦C for at least 20 min. Biofilms were stained with 100 µL of 1% (v/v) solution of
crystal violet (CV) and incubated for 10 min at room temperature. Afterwards, the CV was completely
removed, washing once with PBS and heat-fixed at 65 ◦C for 60 min.
The CV was eluted by the addition of 200 µL of 33% acetic acid. Biofilm formation was measured
at 580 nm using a Microplate reader (EPOCH). The MBIC was defined as the lowest concentration of
drug that resulted in a three-fold decrease of the optical density of 580 nm (OD580) in comparison with
the positive growth-control value. The MBIC50 and MBIC90 values were calculated for all the strains.
4.4. Statical Analysis and Data Processing
The biofilm inhibition rates were calculated using the equation: 100 × (1 − OD580 of the test/OD580
of non-treated control). The MBIC50 and MBIC90 were defined as the lowest concentration that caused
50% and 90% inhibition on the formation of biofilm. Statistical analyses were performed in Prism 8
software (GraphPad Software, Inc., La Jolla, CA, USA). One-way ANOVA was used to compare the
effects of solvents against bacterial biofilms. Two-way ANOVA with Tukey’s test was used to compare
the phylum and solvents using OD values. Differences were considered statistically significant when
p < 0.05. A circular dot plot was created with Tableau Software.
5. Conclusions
The present study provides initial large-scale evidence that microalgae and cyanobacteria are rich
sources of substances with antibiofilm activity. Results demonstrated the importance of (1) employing
a comprehensive extraction protocol in order to increase the chances of detecting bioactive substances;
(2) testing extracts against a range of target microorganisms (because sensitivity to individual extracts
differed among the organisms tested here); and (3) testing extracts from a broad range of source
organisms (because significant differences were observed in the level of activity of extracts from different
microalgal groups). Large-scale screening programs like this are extremely useful for identifying
organisms that warrant further study as producers of bioactive substances of interest. Overall, the
findings of this study provide insights for new opportunities provided by oceans and freshwater
systems in the fight against biofilm infections. Further studies will be made in order to determine
the active compounds responsible of the antibiofilm activity as well as their toxicity to mammal cells
because at extract level toxicity could be due to other components different from the active one.
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p < 0.05 were considered statistically significant. Table S3: Results of Gram-positives strains comparing with
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